Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Amgen Inc
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Bayer AG
Beijing Hanmi Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Genentech Inc
Kymera Therapeutics LLC
Merck & Co Inc
Nyrada Inc
Pfizer Inc
Rigel Pharmaceuticals Inc
TG Therapeutics Inc
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Drug Profiles
AS-2444697 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1830839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1834845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-4948 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KYM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06650833 MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-835 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK-4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for B-Cell Lymphoma and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IRAK4 for Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products
Interleukin 1 Receptor Associated Kise 4 (Rel Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2019: Curis announces advancement to the 200mg BID cohort in the CA-4948 study
Mar 29, 2019: Kymera Therapeutics to present new preclinical data for its first-in-class oral IRAK4 degrader in MYD88-mutant lymphoma at late-breaking session of the American Association for Cancer Research Annual Meeting
Jan 07, 2019: Rigel Pharmaceuticals provides business update on its investigatiol drug R835
Dec 03, 2018: Kymera Therapeutics presents first validation of IRAK4 protein degraders in MYD88-mutant lymphoma
Nov 20, 2018: Curis to present at the 60th annual meeting of the American Society of Hematology
Sep 25, 2018: Noxopharm finds new approach to address chronic inflammation
Jun 26, 2018: Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
Jan 17, 2018: Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kise in Patients with Lymphoma
Mar 30, 2017: Curis to Present Preclinical Data on IRAK4 Kise Inhibitor CA-4948 at AACR Annual Meeting
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-4948 at AACR Annual Meeting
Nov 08, 2015: Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule IRAK4 Program at AACR-NCI-EORTC Intertiol Conference
Apr 20, 2015: TG Therapeutics Presents Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research Annual Meeting
Apr 18, 2015: Aurigene to Present its IRAK-4 Inhibitors Programs at AACR 2015
Apr 14, 2015: Curis Announces Presentation of Data From IRAK-4 Program at AACR Annual Meeting
Nov 12, 2012: Nimbus discovery presents preclinical data on highly selective IRAK4 inhibitors for the treatment of rheumatic diseases.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Products under Development by Companies, H1 2019 (Contd..2), H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Amgen Inc, H1 2019
Pipeline by Astellas Pharma Inc, H1 2019
Pipeline by AstraZeneca Plc, H1 2019
Pipeline by Aurigene Discovery Technologies Ltd, H1 2019
Pipeline by Bayer AG, H1 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Genentech Inc, H1 2019
Pipeline by Kymera Therapeutics LLC, H1 2019
Pipeline by Merck & Co Inc, H1 2019
Pipeline by Nyrada Inc, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by Rigel Pharmaceuticals Inc, H1 2019
Pipeline by TG Therapeutics Inc, H1 2019
Dormant Projects, H1 2019